Approximately 48,000 more Americans have died during the FDA's 48-day delay since this Emergency Use Authorization (EUA) was requested on July 1. Dr. McKinnon's clinical trial found an impressive 51% reduction in deaths if HCQ was begun within 24 hours of admission to the hospital.
An outpatient primary care study by Dr. Vladimir Zelenko, using HCQ, azithromycin and zinc given within less than seven days of COVID-19 symptoms, showed approximately 80% decrease in deaths, and less than 1% of his patients needed to be hospitalized. These extraordinary results show how many lives can be saved with early HCQ treatment.